SCHEMBL5538585

SCHEMBL5538585

CN(C(=S)Nc1c(Cl)c(Cl)cc(Cl)c1Cl)C1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.51
▸ NPC1 O15118 4/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ ABCC1 P33527 4/20 0.47
▸ MAPT P10636 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ ABCG2 Q9UNQ0 1/20 0.45
▸ GAA P10253 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ RAB9A P51151 2/20 0.43
▸ KCNH2 Q12809 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5532573 0.83 ABCC1 (0.51) POLBALDH1A1NPC1KMT2AMEN1
SCHEMBL27782882 0.71 ABCC1 (0.57) POLBALDH1A1NPC1KMT2AMEN1
SCHEMBL5463743 0.71 MAPT (0.77) POLBALDH1A1NPC1KMT2AABCC1
SCHEMBL5524600 0.70 LMNA (0.62) POLBALDH1A1NPC1KMT2AMEN1
SCHEMBL5532869 0.69 POLB (0.73) POLBALDH1A1KMT2AMEN1MAPT
SCHEMBL5538176 0.69 POLB (0.47) POLBALDH1A1NPC1KMT2AMEN1
SCHEMBL11530164 0.68 FAAH (0.55) POLBALDH1A1NPC1KMT2AMEN1
SCHEMBL5527058 0.68 POLB (0.55) POLBALDH1A1NPC1KMT2AMEN1
SCHEMBL5538579 0.68 POLB (0.55) POLBALDH1A1NPC1KMT2AABCC1
SCHEMBL5532884 0.68 POLB (0.55) POLBALDH1A1ABCC1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof ARENA PHARMACEUTICALS, INC. 2007-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010671-A1 Novel quinazoline derivatives and methods of treatment related to the use thereof MCHR1, GPR119, MCHR2 POLB 4518/4885ALDH1A1 2069/4885NPC1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback